(VIANEWS) – The Market ended the session with NYKODE THERAPEUTIC (NYKD.OL) rising 9.32% to kr19.35 on Thursday while Oslo Børs Benchmark Index_GI rose 1.12% to kr1,303.97.
NYKODE THERAPEUTIC’s last close was kr17.70, 49.08% below its 52-week high of kr34.76.
About NYKODE THERAPEUTIC
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, NYKODE THERAPEUTIC has a trailing twelve months EPS of kr-1.53.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.26%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NYKODE THERAPEUTIC’s EBITDA is 310.
Sales Growth
NYKODE THERAPEUTIC’s sales growth is negative 19% for the ongoing quarter and 112.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 31.7% and a negative 4.9%, respectively.
More news about NYKODE THERAPEUTIC (NYKD.OL).
